Gluco-incretin hormones in insulin secretion and diabetes;Incrétines, sécrétion d'insuline et diabète

Medecine/Sciences

Volumn 19, Issue 8-9, 2003, Pages 860-863

  Thorens, Bernard ^a  

^a Institut de Physiologie   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; GASTRIC INHIBITORY POLYPEPTIDE; GASTROINTESTINAL HORMONE; GLUCAGON LIKE PEPTIDE 1; HORMONE DERIVATIVE;

ADIPOSE TISSUE; DIABETES MELLITUS; DIETARY INTAKE; ENZYME ACTIVATION; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE UTILIZATION; HORMONE RECEPTOR INTERACTION; HORMONE RELEASE; HORMONE RESPONSE; HUMAN; INSULIN LIKE ACTIVITY; INSULIN RELEASE; LIVER; MUSCLE; PANCREAS ISLET BETA CELL; REVIEW;

EID: 0141650778     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/20031989860     Document Type: Review

References (24)

1. Orskov C. Glucagon-like peptide-1, a new hormone of the entero-insular axis. Diabetologia 1992; 35: 701-11.
2. Usdin TB, Mezey E, Button DC, Brownstein MJ, Bonner TI. Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology 1993; 133: 2861-70.
3. Thorens B. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide I. Proc Natl Acad Sci USA 1992; 89: 8641-5.
4. Weir GC, Mojsov S, Hendrick GK, Habener JF. Glucagon-like peptide 1 (7-37) actions on endocrine pancreas. Diabetes 1989; 38: 338-42.
5. Ozaki N, Shibasaki T, Kashima Y, et al. cAMP-GEFII is a direct target of cAMP in regulated exocytosis. Nat Cell Biol 2000; 2: 805-11.
6. Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both β-cell replication and neogenesis, resulting in increased β-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999; 48: 2270-6.
7. Tourrel C, Bailbe D, Lacorne M, Meile MJ, Kergoat M, Portha B. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the β-cell mass during the prediabetic period with glucagon-like peptide- 1 or exendin-4. Diabetes 2002; 51: 1443-52.
8. Stoffers DA, Kieffer TJ, Hussain MA, et al. Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 2000; 49: 741-8.
9. Ehses JA, Pelech SL, Pederson RA, McIntosh CHS. Glucose-dependent insulinotropic polypeptide activates the Raf-Mek1/2-ERK1/2 module via a cyclic AMP/cAMP-dependent protein kinase/Rap 1-mediated pathway. J Biol Chem 2002; 277: 37088-97.
10. 2+ influx through L-type voltage-gated calcium channels mediate raf-independent activation of extracellular regulated kinase in response to glucagon-like peptide-1 in pancreatic β-cells. J Biol Chem 2002; 277: 48146-51.
11. Schjoldoger BTG, Mortensen PE, Christiansen J, Ørskov C, Holst JJ. GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans. Dig Dis Sci 1989; 3: 703-8.
12. Wettergren A, Vojdemann M, Holst JJ. Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. Am J Physiol 1998; 275: G984-92.
13. Turton MD, O'SHea D, Gunn I, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996; 379: 69-72.
14. Szayna M, Doyle ME, Betkey JA, et el. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 2000; 141: 1936-41.
15. Lorsen PJ, Tong-Christansen M, Holst JJ, Ørskov C. Distribution of glucagon-like peptide- 1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neuroscience 1997; 77: 257-70.
16. Burcelin R, Dolci W, Thorens B. Glucose sensing by the hepatoportal sensor is GLUT2-dependent. in vivo analysis in GLUT2-null mice. Diabetes 2000; 49: 1643-8.
17. Burcelin R, DaCosta A, Drucker D, Thorens B, Glucose competence of the hepatoporal vein sensor requires the presence of an activated GLP-1 receptor. Diabetes 2001; 50: 1720-8.
18. Scrocchi LA, Brown TJ, MacLusky N, et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide-1 receptor gene. Nat Med 1996; 2: 1254-8.
19. Miyawaki K, Yamada Y, Yano H, et al. Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acod Sci USA 1999; 96: 14843-7.
20. Miyawaki K, Yamada Y, Ban N, et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 2002; 8: 738-42.
21. Rachman J, Gribble FM, Barrows BE, Levy JC, Buchanan KD, Turner RC. Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM. Diabetes 1996; 45: 1524-30.
22. Rachman J, Barrows BA, Levy JC, Turner RC. Near-normalization of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjets with NIDDM. Diabetologia 1997; 40: 205-11.
23. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β cell function in type 2 diabetes: a parallel-group study. Lancet 2002; 359: 824-30.
24. Holst JJ. Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes Metab Res Rev 2002; 18: 430-41.